BrainChip Shares Hit by Dual Pressure as Expired Financing Deal and Sector-Wide Sell-Off Collide
Published on 07/25/2026 at 18:13 | Redaktion boerse-global.de
The forces weighing on BrainChip’s stock right now are coming from two very different directions — and they’re hitting at the same time. One is a mechanical overhang tied to the expiry of an old capital agreement. The other is a sweeping rout that has wiped more than $1.3 trillion from the global semiconductor sector this week alone.
On Friday, shares of the neuromorphic chip designer fell 8.19 percent to close at €0.0740, after touching a fresh 52-week low of €0.0731 during the session. The stock has now lost nearly 19 percent in the past seven trading days and roughly 25 percent over the past month. Over a 12-month horizon, the decline stretches beyond 40 percent.
Expired Put-Option Facility Triggers Forced Share Sales
The most immediate catalyst for Friday’s drop was a technical one. BrainChip confirmed the termination of its put-option agreement with LDA Capital Limited, a financing vehicle the company had used for years as a flexible source of capital. With the facility’s expiration came a termination fee of A$1.0 million.
To cover that obligation, LDA Capital sold roughly 6.96 million BrainChip shares from its collateral holdings. The company plans to place an additional 6.0 million shares onto the market in an orderly fashion over the coming weeks. After deducting an 8.5 percent fee, the net proceeds from those sales will flow back to BrainChip.
Should investors sell immediately? Or is it worth buying BrainChip?
That looming supply of stock is already being priced in, even before the shares actually hit the market. The selling pressure from the LDA unwind explains a significant portion of the recent price weakness — and it’s unlikely to dissipate until the placement is complete.
Broader Chip Rout Adds Macro Weight
But the company’s problems aren’t just internal. The entire semiconductor industry is in the middle of a brutal reassessment. Alphabet and Tesla both reported results this week that reignited concerns about the enormous capital costs tied to artificial intelligence infrastructure. The Philadelphia Semiconductor Index tumbled 4.5 percent on Friday alone, and the global chip sector shed more than $1.3 trillion in value over the week.
For a small-cap name like BrainChip — now carrying a market capitalization of roughly €193 million — those macro tremors hit with amplified force. The company develops the Akida processor for edge-AI applications, a promising niche that offers little insulation when the broader market turns risk-averse.
Adding to the anxiety, reports emerged that the U.S. is planning new tariffs of 10 to 12.5 percent against 60 trading partners, with a specific focus on key chip-producing nations. The prospect of prolonged trade barriers is weighing heavily on the sector and has contributed to BrainChip’s year-to-date loss of around 30 percent.
Technical Indicators Point to Exhaustion — But Not Necessarily a Reversal
The stock’s 14-day relative strength index has fallen to 27.3, deep in oversold territory. In normal circumstances, that would signal the potential for a technical bounce. But the distance from key moving averages tells a different story: BrainChip now trades roughly 24 percent below its 50-day moving average and nearly as far under its 200-day line. The medium-term momentum has detached from every prior support level.
The stock sits almost 47 percent below its October high, and its annualized volatility has climbed above 58 percent — a reflection of just how skittish trading has become. The market is becoming more selective, not uniformly pessimistic. While software names like SAP continue to find favor on the back of cloud growth, speculative AI bets are experiencing their weakest month since 2022. BrainChip, with its pre-revenue technology promise and no established earnings stream to fall back on, fits squarely into that category.
Product Progress Overshadowed
All of this has buried what was actually a positive development for the company. Just days before the sell-off intensified, BrainChip announced an integration partnership with CELUS, a Munich-based provider of cloud-based electronics design automation. The company’s AKD1500 processor and M.2 module will be embedded directly into the CELUS design platform, allowing engineering teams worldwide to integrate edge-AI silicon into their hardware more easily starting in August 2026.
BrainChip at a turning point? This analysis reveals what investors need to know now.
That milestone, along with the planned start of series production for the AKD1500 in the third quarter of 2026 — following initial production deliveries that began over the summer — has been almost entirely overshadowed by the financing and sector-driven selling.
What Comes Next
Investors are now looking toward the company’s quarterly report for June, due in the coming weeks, which should provide clarity on BrainChip’s cash reserves and customer revenue. The remaining 6.0 million shares from the LDA inventory are likely to keep pressure on the stock in the near term. Only once those sales are completed — and the quarterly numbers are in hand — will it become clear whether operational progress can offset the technical and macro headwinds.
An oversold RSI alone won’t be enough to turn the tide. It will take a genuine shift in sentiment, one that reweights the long-term edge-AI story against the immediate costs and trade risks of 2026.
Ad
BrainChip Stock: New Analysis - 25 July
Fresh BrainChip information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
